• Registration number:ЛП-003843
  • International non-proprietary name:atorvastatin
  • Pharmaceutical form:film-coated tablets
  • Pharmacotherapeutic group:lipid lowering agent (HMG-CoA reductase inhibitor)
  • Dosage form:film-coated tablets 10 mg No. 30, film-coated tablets 20 mg No. 30, film-coated tablets 40 mg No. 30
  • Composition:active substance - atorvastatin calcium - 10.85 mg or 21.69, or 43.38 mg, calculated as atorvastatin - 10 mg or 20 mg, or 40 mg.

ATORVASTATIN is a lipid lowering agent belonging to statins group. The antisclerotic effect of the medicinal product is manifested in atorvastatin acting on vascular walls and blood components. Atorvastatin reduces blood plasma viscosity and activity of some coagulation factors, as well as platelet aggregation. Due to the above, it improves the hemodynamics and normalizes the condition of coagulation system.

Indications for use:


  • as an adjunct to diet for reduction of elevated cholesterol, LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, including familial hypercholesterolemia (heterozygous variant) or combined (mixed) hyperlipidemia (corresponding to types IIa and IIb of the Fredrickson classification), when response to the diet and other non-pharmacological measures is inadequate;
  • to reduce total cholesterol and LDL-C in adults with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering types of treatment (for example, LDL apheresis), or if such treatments are unavailable;
  • primary prophylaxis of cardiovascular complications in patients without any clinical signs of ischemic heart disease (IHD), but having some risk factors for its occurrence: age over 55 years, nicotine addiction, arterial hypertension, diabetes mellitus, low blood plasma HDL-C, genetic predisposition, including those secondary to dyslipidemia;
  • secondary prophylaxis of cardiovascular complications in patients with IHD to reduce mortality, occurrence of myocardial infarction, stroke, repeated hospitalization due to angina, and necessity of revascularization procedures.
Method of administration and posology:

For oral administration regardless of food intake, once daily at any but the same time every day.
For adults:
in adult patients, the dose is 10 mg to 80 mg and is selected according to the baseline LDL-C, the purpose and efficacy of given therapy.

Shelf life:

2 years. Do not use after the expiry date.

OJSC "Irbitsky Chemical-Pharmaceutical Plant"